Access to Oncology Medicines Coalition
A UICC-led initiative pioneering access solutions for cancer medicines

The Access to Oncology Medicines Coalition (ATOM Coalition) is a global initiative, led by the Union for International Cancer Control (UICC), in collaboration with over 40 partners across the private and civil society sectors. It aims to address the barriers to availability, affordability and appropriate use of oncology medicines in low- and lower-middle income countries (LLMICs).
The ATOM Coalition ambition
“To reduce suffering and deaths caused by cancer in low- and lower-middle income countries through improved access to and use of essential cancer medicines.”
News and Resources
Latest event
28 May 2025 – ATOM Coalition celebrates three years of advancing access to cancer medicines
Marking three years of progress, UICC-led Access to Oncology Medicines (ATOM) Coalition reflects on key milestones expanding access to cancer medicines in low- and lower middle-income countries (LLMICs).
Latest news
18 August 2025 – UICC welcomes Natasha Madsen Shah as new Executive Director of the ATOM Coalition
UICC is pleased to announce the appointment of Natasha Shah as the new Executive Director of the Access to Oncology Medicines (ATOM) Coalition, effective 18 August 2025.
Natasha brings over 20 years of leadership experience across academia, the pharmaceutical industry, and global health institutions, with a deep commitment to improving access to essential medicines for vulnerable populations, particularly in low- and lower-middle-income countries.
10 June 2025 – ATOM Coalition launches health financing case studies focusing on Georgia, Kenya, the Philippines and Zambia
The UICC-led Access To Oncology Medicines (ATOM) Coalition has proudly launched its first Health Financing Case Studies examining how low- and lower middle-income countries (LLMICs) are addressing cancer financing within the broader context of universal health coverage. Given the high financial toxicity related to out-of-pocket payments for cancer care, the case studies underscore the importance of including essential oncology medicines and diagnostics into UHC.
Three areas of focus
Building on UICC’s long-standing advocacy for the global availability of cancer medicines, the ATOM Coalition is dedicated to identifying and developing access solutions that address key barriers and have the potential to make substantial impact on global efforts to increase access to essential oncology medicines and improve health systems in LLMICs.
Harnessing collective expertise
Guided by the insights of international experts from the UICC global cancer community, the ATOM Coalition Expert Advisory Groups (EAGs) offer invaluable counsel, expertise and recommendations on key issues that impact access to prioritised essential cancer medicines and diagnostics in LLMICs and ATOM Coalition target countries.